SAN DIEGO, Aug. 17, 2016 /PRNewswire/ -- Trovagene,
Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA)
molecular diagnostics, announced today that it has signed an
in-network provider agreement with the healthcare network Blue
Cross Blue Shield of Illinois
(BCBSIL) establishing health benefit access to the full line of
Trovagene's tests and services.
"The agreement with BCBSIL takes us a step further in the
execution of our access and reimbursement strategy that includes
establishing relationships with leading national and regional
payors," said Bill Welch, Chief
Executive Officer of Trovagene. "We are looking forward to offering
oncologists and their patient's access to our Trovera™ urine and
blood based liquid biopsy tests and enabling personalized cancer
care."
Trovagene now has contracts with payors covering approximately
168 million lives. Increasing patient access by contracting
with payors is one of the critical strategic components that
support the adoption of Trovagene's clinical testing in late-stage
solid tumor cancers.
About Blue Cross Blue Shield Illinois
With 8 million members, BCBSIL, a division of Health Care
Service Corporation, a Mutual Legal Reserve Company, is the largest
health insurance company in Illinois. Begun in 1936 in Chicago, BCBSIL remains member owned rather
than publicly traded, and is committed to promoting the health and
wellness of its members and its communities, fostering greater
access to care, and working to lower the overall cost of care while
improving care quality and patient outcomes.
About Trovagene, Inc.
Headquartered in San Diego,
California, Trovagene is leveraging its proprietary
Precision Cancer Monitoring® (PCM) technology for the detection and
monitoring of circulating tumor DNA (ctDNA) in urine and blood. The
Company's technology detects and quantitates oncogene mutations in
cancer patients for improved disease management. Trovagene's PCM
technology is designed to provide important clinical information
beyond the current standard of care, and is protected by
significant intellectual property including multiple issued patents
and pending patent applications globally.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of words
such as "anticipate," "believe," "forecast," "estimated" and
"intend" or other similar terms or expressions that concern
Trovagene's expectations, strategy, plans or intentions. These
forward-looking statements are based on Trovagene's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, substantial
competition; our need for additional financing; uncertainties
of patent protection and litigation; clinical trials involve a
lengthy and expensive process with an uncertain outcome, and
results of earlier studies and trials may not be predictive of
future trial results; uncertainties of government or fourth party
payer reimbursement; limited sales and marketing efforts and
dependence upon fourth parties; and risks related to failure to
obtain FDA clearances or approvals and noncompliance with FDA
regulations. There are no guarantees that any of our technologies
or products will be utilized by oncologists or prove to be
commercially successful, or that Trovagene's strategy to design its
PCM platform to report on clinically actionable cancer genes will
ultimately be successful or result in better reimbursement
outcomes. Trovagene does not undertake an obligation to update or
revise any forward-looking statement. Investors should read
the risk factors set forth in Trovagene's Form 10-K for the year
ended December 31, 2015 and other
periodic reports filed with the Securities and Exchange
Commission.
Trovagene Contacts:
Beth
Anderson
|
Vicki
Kelemen
|
VP, Finance &
Administration
|
Sr. Director,
Marketing Communications
|
858-952-7593
|
858-952-7652
|
ir@trovagene.com
|
vkelemen@trovagene.com
|
Logo - http://photos.prnewswire.com/prnh/20160520/370471LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/blue-cross-blue-shield-illinois-to-cover-trovera-liquid-biopsy-tests-300314592.html
SOURCE Trovagene, Inc.